20 June 2024
Futura
Medical plc
("Futura", "the Group" or the "Company")
Result of
AGM
Futura Medical plc (AIM: FUM), the
consumer healthcare company behind Eroxon®, that specialises in the
development and global commercialisation of innovative and
clinically proven sexual health products, today announces that at
its Annual General Meeting, held today at 10:00am BST, the
shareholders duly passed all resolutions.
The total number of votes received
on each resolution were as follows:
|
|
Voting
For
|
Voting
Against
|
|
|
|
Number of
votesi
|
%
|
Number of votes
|
%
|
Total Votes
|
% ISC
|
Votes
withheldii
|
|
Resolution 1
|
To receive and adopt the annual
report and accounts for the financial year ended 31 December
2023
|
145,896,305
|
99.50
|
738,451
|
0.50
|
146,634,756
|
48.57
|
121,536
|
|
Resolution 2
|
That Roy Davis be and is hereby
appointed as a Director of the Company.
|
146,637,030
|
99.98
|
30,544
|
0.02
|
146,667,574
|
48.58
|
91,718
|
|
Resolution 3
|
To re-elect Angela Hildreth as a
Director of the Company, who retires by rotation in accordance
with
the Company's articles of
association.
|
146,583,928
|
99.94
|
80,896
|
0.06
|
146,664,824
|
48.58
|
91,468
|
|
Resolution 4
|
To re-appoint Grant Thornton UK LLP
as auditor of the Company to hold office until the conclusion
of
the next annual general meeting of
the Company.
|
146,559,436
|
99.95
|
74,813
|
0.05
|
146,634,249
|
48.57
|
122,043
|
|
Resolution 5
|
To authorise the Directors to
determine the remuneration of Grant Thornton UK LLP as auditor of
the
Company
|
146,544,066
|
99.95
|
68,860
|
0.05
|
146,612,926
|
48.56
|
143,366
|
|
Resolution 6
|
That the Directors are generally and
unconditionally authorised for the purposes of section
551
Companies Act 2006 (the "CA 2006")
to exercise all the powers of the Company to allot shares in
the
Company and to grant rights to
subscribe for or to convert any security into shares in the
Company.
|
146,000,585
|
99.50
|
735,009
|
0.50
|
146,735,594
|
48.60
|
20,698
|
|
Resolution
7iii
|
Disapplication of pre-emption
rights
|
145,446,404
|
99.13
|
1,279,733
|
0.87
|
146,726,137
|
48.60
|
30,155
|
|
Resolution 8
iii
|
Disapplication of pre-emption rights
in respect of an additional 20% of the company issued share
capital
|
146,060,258
|
99.54
|
669,879
|
0.46
|
146,730,137
|
48.60
|
26,155
|
|
|
|
|
|
|
|
|
|
| |
ⁱ Where
shareholders appointed the Chairman as their proxy with discretion
as to voting, their votes were cast in favour of the
resolution
ⁱⁱ A vote
withheld is not a vote in law and is not counted towards the votes
cast "For" or "Against" a resolution
ⁱⁱⁱ Special
Resolution (75% majority required)
The total voting rights of the
Company as at 10:00 am on 18 June 2024 (the time by which
shareholders wanting to vote at the AGM were required to be entered
on the register) was 301,863,641 ordinary shares of 0.2p each. The
Company does not hold any shares in treasury.
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Liberum
Nominated Adviser
and Broker
|
Richard Lindley
Nikhil Varghese
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma
Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the
developer of innovative sexual health products, including lead
product Eroxon. Our core strength lies in our research, development
and commercialisation of topically delivered gel formulations in
sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally
across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men
under 40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper Consumer
Health in Europe. Eroxon has been nominated for a number of
healthcare industry awards and has won two to-date.